Autologous Plasma Rich in Growth Factors (PRGF) Treating the Symptomatic Knee OA

Biotechnology Institute IMASD240 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of PRGF infiltrations in the treatment of knee osteoarthritis.

Several studies have shown the positive effects of the autologous "Preparation Rich in Growth Factors" (PRGF) in different clinical situations involving connective tissues and also in OA synovial cells. PRGF is a biological delivery system of a complex mixture of bioactive proteins essential to natural repair including anabolic factors for cartilage such as transforming growth factor-β1 (TGF-β1), platelet-derived growth factor (PDGF) and insulin-like growth factor (IGF-I). The potential of PRGF to enhance the limited capacity of cartilage to repair itself encouraged the idea of treating degenerative joint conditions with this autologous preparation. The present study was undertaken to assess the efficacy and safety of the intra-articular injection of PRGF and to obtain useful information about the clinical effects. Since pain is the most pressing problem facing people with OA, a significant improvement in pain would indicate the potential of the proposed treatment. We will also evaluate functionality and quality of life. In addition we will examine changes in novel serum and synovial fluid biomarkers and their correlation with MRI-based parameters in a subgroup of patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

240

Conditions

Joint Disease

Interventions

PRGF Intraarticular injectionDEVICE

Three consecutive PRGF injections each one week apart.

Hyaluronic Acid Intraarticular injectionDEVICE

Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.

Eligibility

Sex: ALLMin age: 40 YearsMax age: 72 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients of both sexes and aged between 40 and 72 years. * Diagnosed with osteoarthritis of the knee by radiological image. * Pain in the joint equal to or greater than 2.5 points in EAV. * Radiological severity:Value in the Ahlback score 3 or less. * Body mass index between 20 and 30. * Possibility for observation during follow-up period. Exclusion Criteria: * Bilateral Gonarthrosis requiring infiltration in both knees. * Body mass index greater than 30. * Diagnosed polyarticular disease. * Severe mechanical deformation. * Previous arthroscopy in the past year. * Intraarticular infiltration of hyaluronic acid in the last 6 months. * Rheumatic autoimmune systemic disease. * Poorly controlled diabetes mellitus. * Blood alterations. * Immunosuppressive treatments and/or coumarinics. * Treatment with steroids for 3 months prior to its inclusion in the study. * Treatment with nonsteroidal anti-inflammatory drugs for 15 days prior to its inclusion in the study.

Locations (3)

UCA (Unidad de Cirugía Artroscopica Mikel Sanchez.) Clinica USP La Esperanza.

Vitoria-Gasteiz, Alava, Spain

Hospital Donostia.

Donostia / San Sebastian, Gipuzkoa, Spain

Policlinica Gipuzkoa

Donostia / San Sebastian, Gipuzkoa, Spain

Outcomes

Primary Outcomes

Improvement in Womac pain subscore and visual analogue score from baseline and changes in Lequesne's algofunctional index.

Time frame: 6 months

Secondary Outcomes

Improvement of joint function (change in Womac OA index total score and function and stiffness subscores.)

Time frame: 6 months

Changes in Quality of life (SF-12 questionnaire).

Time frame: 6 months

Changes in Degree of joint mobility.(determined by goniometer).

Time frame: 6 months

Complications and/or adverse effects.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.